|
Mutation Information
|
Mutation Site
|
E138K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
bictegravir (BIC);emtricitabine (FTC);tenofovir alafenamide;rilpivirine (RPV) |
|
Country
|
Australia;Europe;North America |
Literature Information
|
PubMed PMID
|
31430369
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2019 |
|
Journal
|
The Journal of antimicrobial chemotherapy |
|
Title
|
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. |
|
Author
|
Andreatta K,Willkom M,Martin R,Chang S,Wei L,Liu H,Liu YP,Graham H,Quirk E,Martin H,White KL |
|
Evidence
|
Table3;Table 4;NNRTI-R substitutions were observed in 23% (124/543) of participants; the most frequently detected substitutions were K103N/S in 12% (64/543) and rilpivirine-associated resistance substitutions (L100I, K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C or M320I/L) in 10% (53/543) (Table 3).
|
|
|
HIV Mutation Detail Information